• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

n.burdett@unimelb.edu.au

Credentials


Position
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0001-8581-2048

Dr Nikki Burdett

Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology

25 Scholarly works
3 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Comparison of homologous recombination deficiency scoring methods in multi-site samples in high grade serous ovarian cancer
    DOI: 10.1016/j.ijgc.2025.104233
  • 2026

    Journal article

    Rethinking ovarian cancer III: the past decade and future directions
    DOI: 10.1038/s41568-026-00916-0
  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Identifying the Key to Treatment Resistance in Ovarian Cancer
  • 2026

    Research grants (other domestic)

    Targeting Whole Genome Doubling as a Therapeutic Vulnerability in Ovarian Cancer
  • 2025

    Journal article

    Abstract B004: Evaluating spatial inter-tumor heterogeneity in whole genome duplication states and homologous recombination deficiency status in advanced ovarian high grade serous carcinoma
    DOI: 10.1158/1538-7445.ovarian25-b004
  • 2025

    Journal article

    Genome doubling fuels ovarian cancer evolution and immune dysregulation
    DOI: 10.1038/d41586-025-02059-y
  • 2024

    Research grants (other domestic)

    Stereotactic Ablative Body Radiotherapy (SABR) for 4 Gynaecologic Metastases
Nikki Burdett

RECENT SCHOLARLY WORKS

  • 2024

    Journal article

    Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer
    DOI: 10.1038/s41467-024-50137-y
  • 2024

    Journal article

    Planetary care is good cancer care
    DOI: 10.5694/mja2.52455
  • 2024

    Conference Proceedings

    EV243/#1235 Genomic characteristics underlying homologous recombination deficient-negative scores in ovarian high grade serous cancer tumors
    DOI: 10.1136/ijgc-2024-igcs.362
  • 2024

    Conference Proceedings

    Beacon: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer.
    DOI: 10.1200/JCO.2024.42.16_suppl.5565
  • 2024

    Conference Proceedings

    Inter-tumor heterogeneity revealed by multi-site whole genome sequencing of high grade serous ovarian cancer
    DOI: 10.1158/1538-7445.OVARIAN23-A057
  • 2024

    Conference Proceedings

    Effect of spatial and temporal inter-tumoral heterogeneity on homologous recombination deficiency scores in high grade serous ovarian cancer
    DOI: 10.1158/1538-7445.OVARIAN23-B114

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224